Global Post-traumatic Stress Disorder Therapeutics Market to grow at a CAGR of 1.09% over the period 2014-2019, Finds New Report

Report forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.

PTSD is a psychological condition that develops after a person is exposed to any traumatic event, and it drains a person emotionally. According to the DSM-IV codes found in the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association (APA), PTSD is classified under anxiety disorders. PTSD can occur in individuals of any age, irrespective of the gender; its symptoms can develop immediately after a traumatic event or during the course of time. Its symptoms normally include re-experience of the traumatic event, avoidance of the incidents, and abnormal mood swings. Treatments for PTSD include psychological counselling, which help in identifying the cause of the condition and providing counselling to come out of the situation. Medications present in the market help in reducing the symptoms during the course of the treatment.

This report covers the present scenario and the growth prospects of the global PTSD therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of PTSD. This report includes the segmentation of the market based on geography.

Key Regions

• Americas
• APAC
• EMEA       

According to the report, increased cases of accidents and violence boost market growth. The rise in conflicts between different countries has increased stress levels in individuals worldwide, particularly those in the military. Domestic and social violence also trigger the development of PTSD in people.

Key players in the Global PTSD Therapeutics Market: GlaxoSmithKline plc, Pfizer Inc. and Otsuka Pharmaceutical Co. Ltd.

Other Prominent Vendors in the market are: Abbott Laboratories, Addex Therapeutics, AstraZeneca, Azevan Pharmaceuticals, Baylor Research Institute, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, Eli Lilly, F. Hoffmann-La Roche, Forest Laboratories, H. Lundbeck, Humanetics Pharmaceuticals, Intra-Cellular Therapies, Janssen Pharmaceuticals, Luye Pharma, Marinus Pharmaceuticals, Nanotherapeutics, Naurex, Neurocrine Biosciences, Novartis Pharmaceuticals, Suven, Synchroneuron, Takeda Pharmaceutical, Teva Pharmaceutical and Tonix Pharmaceuticals

Market Driver

• Growing Number of Accidents and Violence Worldwide
• For a full, detailed list, view our report

Market Challenge

• Unavailability of Standard Diagnostic Methods
• For a full, detailed list, view our report

Market Trend

• Rise in Public Awareness
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 71 pages, “Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019” report covers Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Product Profiles, Introduction, PTSD Overview, Pipeline Analysis, Market Landscape, Market Segmentation by Class of Drug, Geographical Segmentation, Buying Criteria, Market Growth Drivers, Drivers and Their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and Their Impact, Vendor Landscape, Global PTSD Therapeutics Market: Key Takeaways, Key Vendor Analysis.

For further information on this report, please visit- http://mrr.cm/4L4

Find all Treatments Reports at: http://www.marketresearchreports.com/treatments